Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy

NCT00801853 is registered in ClinicalTrials.gov with Aerovance, Inc. as lead sponsor.

NCT NCT00801853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00801853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy
Lead sponsor
Aerovance, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
February 28, 2010
Enrollment
424 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

asthma